Our Programmes
We are developing a Drug-Eluting Bead (CellBead Neuro) for the treatment of neurological trauma and neurological degeneration.
Accessibility information | Access Keys


We are developing a Drug-Eluting Bead (CellBead Neuro) for the treatment of neurological trauma and neurological degeneration.
CellMed AG is based in Alzenau, Germany and makes medical device and pharmaceutical products. CellMed was acquired by Biocompatibles in 2005
Biocompatibles International plc is a leading medical technology company in the field of drug-device combination products.
The Oncology Products Division conducts the marketing of Biocompatibles’ approved oncology products, supplied from facilities in Farnham, UK and Oxford, CT. These include Drug-Eluting Bead products which are used in more than 35 countries for the treatment of primary liver cancer (HCC), liver metastases from colorectal cancer, and other cancers; and Brachytherapy products (Radiation-Delivering Seeds) which are used in the treatment of prostate cancer. Our distribution partners include AngioDynamics Inc., Terumo Corporation and Eisai Co. Ltd.
Our R&D Facilities are engaged in licensing and in new product development, based on the company’s core drug delivery technologies. The Drug Delivery Division, in Farnham, UK is developing new products for oncology. CellMed, in Alzenau, Germany, is developing a Drug-Eluting Bead product for the treatment of stroke, based on proprietary stem cell technology; and a GLP-1 analogue for the treatment of diabetes and obesity partnered with AstraZeneca. We also have collaborative agreements with Bayer Healthcare Pharmaceuticals Inc., Medtronic Inc. and Merz Pharmaceuticals GmbH.
Trading Statement - 08/01/2010
AstraZeneca and Biocompatibles agree to initiate Clinical Trial Programme - 06/12/2009
Acquisition of Cancer Diagnostic Product and Related Intellectual Property - 12/11/2009
© 2010 Biocompatibles UK Ltd - All rights reserved - Site map - Terms & conditions - Accessiblity - Help - Glossary